Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000041089
JPRN-UMIN000041089
Completed
未知

Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patients - Comparative efficacy of triple therapies

ippon Koukan Hospital0 sites50 target enrollmentJuly 14, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOPD

Overview

Phase
未知
Intervention
Not specified
Conditions
COPD
Sponsor
ippon Koukan Hospital
Enrollment
50
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 14, 2020
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ippon Koukan Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •patients with HOT

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPD
EUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000
Completed
Phase 4
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY ELLIPTA) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting.(study 206854)
NL-OMON48721GlaxoSmithKline700